- Home
- PHVS vs AZTA Comparison
PHVS vs AZTA Comparison
Compare PHVS & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- AZTA
- Stock Information
- Founded
- PHVS 2015
- AZTA 1978
- Country
- PHVS Switzerland
- AZTA United States
- Employees
- PHVS N/A
- AZTA N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- AZTA Industrial Machinery/Components
- Sector
- PHVS Health Care
- AZTA Technology
- Exchange
- PHVS Nasdaq
- AZTA Nasdaq
- Market Cap
- PHVS 1.3B
- AZTA 1.4B
- IPO Year
- PHVS 2021
- AZTA 1995
- Fundamental
- Price
- PHVS $21.65
- AZTA $30.26
- Analyst Decision
- PHVS Buy
- AZTA Buy
- Analyst Count
- PHVS 6
- AZTA 4
- Target Price
- PHVS $36.67
- AZTA $42.00
- AVG Volume (30 Days)
- PHVS 118.6K
- AZTA 716.0K
- Earning Date
- PHVS 08-12-2025
- AZTA 08-05-2025
- Dividend Yield
- PHVS N/A
- AZTA N/A
- EPS Growth
- PHVS N/A
- AZTA N/A
- EPS
- PHVS N/A
- AZTA N/A
- Revenue
- PHVS N/A
- AZTA $668,821,000.00
- Revenue This Year
- PHVS N/A
- AZTA N/A
- Revenue Next Year
- PHVS N/A
- AZTA $4.18
- P/E Ratio
- PHVS N/A
- AZTA N/A
- Revenue Growth
- PHVS N/A
- AZTA 12.46
- 52 Week Low
- PHVS $11.51
- AZTA $23.91
- 52 Week High
- PHVS $26.33
- AZTA $55.64
- Technical
- Relative Strength Index (RSI)
- PHVS 47.92
- AZTA 48.82
- Support Level
- PHVS $21.56
- AZTA $29.72
- Resistance Level
- PHVS $24.52
- AZTA $31.80
- Average True Range (ATR)
- PHVS 1.32
- AZTA 1.13
- MACD
- PHVS -0.07
- AZTA 0.05
- Stochastic Oscillator
- PHVS 28.04
- AZTA 57.18
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.